Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 30;17(4):2000-2013.
doi: 10.21037/jtd-24-1805. Epub 2025 Apr 24.

The role of postoperative radiotherapy for invasive thymic epithelial tumors: a single-center experience

Peng Zhang #  1 , Yongjia Chai #  2 , Peng Zhang  2
Affiliations

The role of postoperative radiotherapy for invasive thymic epithelial tumors: a single-center experience

Peng Zhang et al. J Thorac Dis. .

Abstract

Background: Surgery is the primary treatment modality for thymic epithelial tumors (TETs). However, the efficacy of postoperative radiotherapy (PORT) in the management of thymoma remains a topic of debate. This study aimed to evaluate the role of PORT in improving clinical outcomes for patients with thymoma.

Methods: We retrospectively analyzed data from patients who underwent surgery for TETs at the Cardiovascular Thoracic Surgery Department, Tianjin Medical University General Hospital from October 2001 to July 2021. Patients classified as Masaoka-Koga stage II to IVA were included in the study. The impact of PORT on relapse-free survival (RFS) and overall survival (OS) was assessed using the Kaplan-Meier method and Cox proportional hazards regression analysis.

Results: A total of 211 thymoma patients were included in this study, among whom 141 cases (66.8%) underwent PORT. Overall, PORT was not associated with a significant improvement in OS or RFS in the entire cohort. However, in patients with locally advanced disease, PORT for Masaoka-Koga stage III-IVA thymoma was significantly associated with improved OS (P=0.01), although it did not result in a significant improvement in RFS (P=0.12). Subgroup analyses revealed that PORT significantly improved OS (P=0.042) in patients with Masaoka-Koga stage III thymoma. Furthermore, among patients with tumor-node-metastasis (TNM) stage III thymoma [according to the Union for the International Cancer Control (UICC) TNM Classification, 8th Edition], the PORT group exhibited significantly better RFS (P=0.03) and OS (P=0.01). Cox regression analysis demonstrated that TNM stage was the only statistically significant factor influencing OS in univariate analysis among patients with aggressive thymoma [TNM stage I-II vs. TNM stage III, hazard ratio (HR): 5.669, 95% confidence interval (CI): 1.347-23.852, P=0.02]. In addition, PORT was the only statistically significant factor influencing OS in univariate analysis for patients with TNM stage III thymoma (PORT vs. non-PORT, HR: 13.646, 95% CI: 1.522-122.356, P=0.02).

Conclusions: PORT plays a significant role in the management of thymoma patients. For patients with Masaoka-Koga stage II thymoma, the potential benefits of PORT require further investigation. In patients with Masaoka-Koga stage III-IVA thymoma, PORT is associated with improved OS but does not appear to prevent disease recurrence. Additionally, among TNM stage III patients, the PORT group demonstrated significantly better RFS and OS. TNM stage is a potentially independent prognostic factor for survival in patients with aggressive thymoma, while PORT represents a critical prognostic factor for survival in patients with TNM stage III thymoma.

Keywords: Postoperative radiotherapy (PORT); thymoma; tumor-node-metastasis stage (TNM stage).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-1805/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Kaplan-Meier plots and log-rank P values for PORT versus non-PORT: (A) overall survival for all thymoma patients, (B) relapse-free survival for all thymoma patients. PORT, postoperative radiotherapy.
Figure 2
Figure 2
Kaplan-Meier plots and log-rank P values for Masaoka-Koga stage II versus Masaoka-Koga stages III and IVA. (A) Overall survival for thymoma patients; (B) relapse-free survival for thymoma patients. Kaplan-Meier plots and log-rank P values for PORT versus non-PORT: (C) overall survival for Masaoka-Koga stage II thymoma patients; (D) relapse-free survival for Masaoka-Koga stage II thymoma patients. PORT, postoperative radiotherapy.
Figure 3
Figure 3
Kaplan-Meier plots and log-rank P values for PORT versus non-PORT. (A) Overall survival for Masaoka-Koga stage III and IVA thymoma patients; (B) relapse-free survival for Masaoka-Koga stage III and IVA thymoma patients; (C) overall survival for Masaoka-Koga stage III thymoma patients; (D) relapse-free survival for Masaoka-Koga stage III thymoma patients. PORT, postoperative radiotherapy.
Figure 4
Figure 4
Kaplan-Meier plots and log-rank P values for TNM stages I and II versus TNM stage III. (A) overall survival for thymoma patients; (B) relapse-free survival for thymoma patients. Kaplan-Meier plots and log-rank P values for PORT versus non-PORT: (C) overall survival for TNM stages I and II thymoma patients; (D) relapse-free survival for TNM stages I and II thymoma patients. PORT, postoperative radiotherapy; TNM, tumor-node-metastasis.
Figure 5
Figure 5
Kaplan-Meier plots and log-rank P values for PORT versus non-PORT. (A) Overall survival for TNM stage III thymoma patients; (B) relapse-free survival for TNM stage III thymoma patients. PORT, postoperative radiotherapy; TNM, tumor-node-metastasis.
See this image and copyright information in PMC

References

    1. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010;5:S260-5. 10.1097/JTO.0b013e3181f1f62d - DOI - PMC - PubMed
    1. de Jong WK, Blaauwgeers JL, Schaapveld M, et al. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008;44:123-30. 10.1016/j.ejca.2007.11.004 - DOI - PubMed
    1. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-92. 10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R - DOI - PubMed
    1. Koga K, Matsuno Y, Noguchi M, et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 1994;44:359-67. 10.1111/j.1440-1827.1994.tb02936.x - DOI - PubMed
    1. Ruffini E, Detterbeck F, Van Raemdonck D, et al. Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database. J Thorac Oncol 2014;9:541-8. 10.1097/JTO.0000000000000128 - DOI - PubMed